Latest news with #BostonScientific
Yahoo
2 days ago
- Business
- Yahoo
GE HealthCare raises annual profit forecast on smaller tariff impact
(Reuters) -GE HealthCare Technologies raised annual profit forecast on Wednesday, as the medical device maker expects a smaller hit from tariffs. The company expects adjusted profit of $4.43 to $4.63 per share for 2025, compared with its previous range of $3.90 to $4.10 per share. The forecast includes a 45-cent-per-share impact from tariffs, which is lower than the 85 cents or $500 million hit it expected in April. Other medical device maker Boston Scientific and healthcare conglomerate Johnson & Johnson, whose costs were exclusively tied to its medtech unit, also halved their expectations for tariff-related costs for the year to about $100 million and $200 million, respectively. GE HealthCare expects annual organic revenue growth of 3%, compared with its previous forecast of a 2% to 3% increase. analyst Robbie Marcus said the company's outlook was "good enough as a more in-line organic growth performance is balanced against conservative tariff assumptions that could/will likely leave upside on the table". GE HealthCare also beat Wall Street estimates for second-quarter profit and revenue, driven by growth in its all four businesses. Revenue at imaging devices, the company's largest segment, grew 2% during the period. Its other units are advanced visualization solutions, patient care solutions and pharmaceutical diagnostics. Medical device manufacturers have been benefiting from still-high demand for elective surgical procedures in the United States, especially among older adults. GE HealthCare's total revenue came in at $5.01 billion during the quarter ended June 30, compared with analysts' average estimate of $4.96 billion, according to data compiled by LSEG. On an adjusted basis, it earned $1.06 per share, compared with the estimate of 92 cents per share. The company said its adjusted core margin was down 80 basis points during the quarter, impacted by tariffs.
Yahoo
2 days ago
- Business
- Yahoo
GE HealthCare raises annual profit forecast on smaller tariff impact
(Reuters) -GE HealthCare Technologies raised annual profit forecast on Wednesday, as the medical device maker expects a smaller hit from tariffs. The company expects adjusted profit of $4.43 to $4.63 per share for 2025, compared with its previous range of $3.90 to $4.10 per share. The forecast includes a 45-cent-per-share impact from tariffs, which is lower than the 85 cents or $500 million hit it expected in April. Other medical device maker Boston Scientific and healthcare conglomerate Johnson & Johnson, whose costs were exclusively tied to its medtech unit, also halved their expectations for tariff-related costs for the year to about $100 million and $200 million, respectively. GE HealthCare expects annual organic revenue growth of 3%, compared with its previous forecast of a 2% to 3% increase. analyst Robbie Marcus said the company's outlook was "good enough as a more in-line organic growth performance is balanced against conservative tariff assumptions that could/will likely leave upside on the table". GE HealthCare also beat Wall Street estimates for second-quarter profit and revenue, driven by growth in its all four businesses. Revenue at imaging devices, the company's largest segment, grew 2% during the period. Its other units are advanced visualization solutions, patient care solutions and pharmaceutical diagnostics. Medical device manufacturers have been benefiting from still-high demand for elective surgical procedures in the United States, especially among older adults. GE HealthCare's total revenue came in at $5.01 billion during the quarter ended June 30, compared with analysts' average estimate of $4.96 billion, according to data compiled by LSEG. On an adjusted basis, it earned $1.06 per share, compared with the estimate of 92 cents per share. The company said its adjusted core margin was down 80 basis points during the quarter, impacted by tariffs. Sign in to access your portfolio
Yahoo
2 days ago
- Business
- Yahoo
Baxter (BAX) Reports Earnings Tomorrow: What To Expect
Healthcare company Baxter International (NYSE:BAX) will be reporting earnings this Thursday before market hours. Here's what to expect. Baxter beat analysts' revenue expectations by 1.9% last quarter, reporting revenues of $2.63 billion, up 5.4% year on year. It was a very strong quarter for the company, with a solid beat of analysts' constant currency revenue estimates and an impressive beat of analysts' EPS estimates. Is Baxter a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Baxter's revenue to grow 4.7% year on year to $2.82 billion, in line with the 4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.61 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Baxter has missed Wall Street's revenue estimates six times over the last two years. Looking at Baxter's peers in the medical devices & supplies - diversified segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Neogen reported a revenue decline of 4.8%, topping estimates by 1.3%. Boston Scientific traded up 2.9% following the results. Read our full analysis of Boston Scientific's results here and Neogen's results here. Investors in the medical devices & supplies - diversified segment have had fairly steady hands going into earnings, with share prices down 1.8% on average over the last month. Baxter is down 5.2% during the same time and is heading into earnings with an average analyst price target of $37.09 (compared to the current share price of $28.70). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings
Medical technology company Hologic (NASDAQ:HOLX) will be reporting earnings this Wednesday afternoon. Here's what investors should know. Hologic met analysts' revenue expectations last quarter, reporting revenues of $1.01 billion, down 1.2% year on year. It was a slower quarter for the company, with a slight miss of analysts' full-year EPS guidance estimates and full-year revenue guidance meeting analysts' expectations. Is Hologic a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Hologic's revenue to be flat year on year at $1.01 billion, slowing from the 2.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.05 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hologic has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 0.9% on average. Looking at Hologic's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. Hologic is up 2.8% during the same time and is heading into earnings with an average analyst price target of $69.93 (compared to the current share price of $66.99). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
3 days ago
- Business
- Yahoo
CONMED (CNMD) Q2 Earnings: What To Expect
Medical tech company CONMED (NYSE:CNMD) will be announcing earnings results this Wednesday after market close. Here's what to look for. CONMED beat analysts' revenue expectations by 2.6% last quarter, reporting revenues of $321.3 million, up 2.9% year on year. It was a very strong quarter for the company, with a solid beat of analysts' full-year EPS guidance estimates and an impressive beat of analysts' EPS estimates. Is CONMED a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting CONMED's revenue to grow 1.9% year on year to $338.3 million, slowing from the 4.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.12 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. CONMED has missed Wall Street's revenue estimates three times over the last two years. Looking at CONMED's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. CONMED is down 4% during the same time and is heading into earnings with an average analyst price target of $66.60 (compared to the current share price of $50.02). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
